Loading organizations...
§ Private Profile · Amsterdam, Noord-Holland, The Netherlands
Biotech developing first-in-class small molecule inhibitors for precision oncology, focused on difficult-to-treat cancers.
Flindr Therapeutics is an Oss, Netherlands-based biotechnology company that develops first-in-class small molecule inhibitors for precision oncology treatments. The pre-clinical stage firm utilizes its proprietary ImmunoGram Drug Discovery Engine to identify novel targets in cancer and immune cells, aiming to restore immune responses and eradicate tumors in specific patient populations. The enterprise was founded in 2020 as a spin-out from the Netherlands Cancer Institute and Oncode Institute by Maarten Ligtenberg, Daniel Peeper, and Christian Blank. In 2024, the business secured a €20 million Series A financing round led by V-Bio Ventures, with participation from Johnson & Johnson Innovation JJDC, to advance its therapeutic pipeline including the lead RNF31 program. To further accelerate its oncology drug discovery efforts targeting difficult-to-treat cancers, the organization recently expanded its strategic collaboration with CrystalsFirst and joined forces with VIB in 2023.
Flindr Therapeutics has raised $21.4M across 1 funding round.
Flindr Therapeutics has raised $21.4M in total across 1 funding round.
Flindr Therapeutics has raised $21.4M across 1 funding round. Most recently, it raised $21.4M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 24, 2024 | $21.4M Series A | Christina Takke | BOM, Curie Capital, Tine Bekaert, Johnson & Johnson Innovation, Chris DE Jonghe, Cedric VAN Nevel, Swanbridge Capital | Announced |
Flindr Therapeutics has raised $21.4M in total across 1 funding round.
Flindr Therapeutics's investors include Christina Takke, BOM, Curie Capital, Tine Bekaert, Johnson & Johnson Innovation, Chris De Jonghe, Cedric Van Nevel, Swanbridge Capital.